BioSpace's List of April 2019 Life Science IPOs

April 2019 IPO Filings and Pricings, Updated 4/30/19

Know of an IPO since April 1, 2019 that we missed? Email us at  

Related: Check out BioSpace's January list, February list, and March list

Date Company Name Amount (USD) Company HQ Research Focus
4/29/19 Codiak BioSciences $86.25M Filed Seattle, WA Exosome therapeutics in I/O and infectious diseases
4/26/19 Peloton Therapeutics $115M Filed Dallas, TX Modulating HIF-2-alpha to treat cancer and other diseases
4/26/19 Bicycle Therapeutics $86.25M Filed Cambridge, UK Bicycle technology against multiple oncology targets 
4/26/19 IDEAYA Biosciences $70M Filed South San Francisco, CA Precision medicine targeting oncogenetic pathways and synthetic lethality
4/26/19 Karuna Pharmaceuticals Undisclosed Filing Boston, MA Muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment in CNS disorders
4/17/19 Hookipa $84M Priced New York City, NY Immunotherapeutics for infectious diseases and cancers using arenavirus platform
4/17/19 Brainsway $27.5M Priced Jerusalem, Israel Deep TMS technology for the treatment of MDD and OCD
4/17/19 Turning Point Therapeutics $166.5M Priced San Diego, CA Small molecule, targeted oncology therapies to address key limitations of existing therapies
4/12/19 NextCure $86.25M Filed Beltsville, MD Immunomedicines to treat cancer and other immune-related diseases
4/12/19 Cortexyme $86.25M Filed South San Francisco, CA Novel treatments for altering the course of neurodegenerative diseases
4/12/19 Applied Therapeutics $86.25M Filed New York City, NY Cutting-edge technology to validated drug targets in areas of high unmet medical need
4/12/19 Milestone Pharmaceuticals $86.25M Filed Montreal, Quebec, Canada Developing and commercializing etripamil for the treatment of cardiovascular indications
4/5/19 TransMedics $86.25M Filed Andover, MA Organ transplant therapy for end-stage organ failure patients across multiple disease states
4/5/19 Trevi Therapeutics $86.25M Filed New Haven, CT Nalbuphine ER to treat serious neurologically mediated conditions
4/5/19 Guardion Health Sciences, Inc. $6M Priced San Diego, CA Targeted ocular nutrition and diagnostic technology for eye diseases
4/4/19 Silk Road Medical  $120M Priced Sunnyvale, CA Medical devices to improve the treatment of carotid artery disease
4/4/19 NGM Biopharmaceuticals $106.7M Priced South San Francisco, CA Transformative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases













Back to news